This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:mp:minocycline [03.25.2012] – [Dosing and administration] joyful | home:mp:minocycline [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 2: | Line 2: | ||
====== Minocycline | ====== Minocycline | ||
- | Minocycline hydrochloride, | ||
- | Minocycline is recognized as a DMARD (Disease-Modifying Anti-Rheumatic Drug) by the American College of Rheumatology, | + | Minocycline hydrochloride, |
+ | |||
+ | Minocycline is recognized as a DMARD (Disease-Modifying Anti-Rheumatic Drug) by the American College of Rheumatology, | ||
Either generic or brand name is appropriate to use. | Either generic or brand name is appropriate to use. | ||
+ | |||
+ | <note important> | ||
+ | |||
Line 58: | Line 62: | ||
- | Minocycline has been in use for over 40 years yet continues to be effective against MRSA(({{pubmed> | + | Minocycline has been in use for over 40 years yet continues to be effective against MRSA(({{pmid> |
- | ===== Combining minocycline with other Marshall Protocol antibiotics ===== | + | |
- | |||
- | < | ||
- | |||
- | //**Trevor Marshall, PhD**//</ | ||
- | |||
- | |||
- | |||
- | Minocycline may be combined with other MP antibiotics in the following fashion: | ||
- | |||
- | * **BCM** – Bactrim DS + clindamycin + minocycline | ||
- | * **CDM** – clindamycin + demeclocycline + minocycline | ||
- | * **CMZ** – clindamycin + minocycline + Zithromax | ||
- | * **DMZ** – demeclocycline + minocycline + Zithromax | ||
- | |||
- | Because demeclocycline and minocycline are similar, using the antibiotics in the same combination may offer a less severe immunopathological reaction than any of the other combinations. | ||
- | {{tag>antibiotics}} | + | {{tag>Other_medication MP}} |
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
Line 88: | Line 77: | ||
Chef Bama</ | Chef Bama</ | ||
- | [[http:// | + | [[https:// |
Line 97: | Line 86: | ||
Minocycline, | Minocycline, | ||
- | //**BW Festoff**// (({{pubmed> | + | //**BW Festoff**// (({{pmid> |
- | Also, minocycline partially inhibits caspase-3 activation and photoreceptor degeneration after photic injury.(({{pubmed> | + | Also, minocycline partially inhibits caspase-3 activation and photoreceptor degeneration after photic injury.(({{pmid> |
< | < | ||
- | Minocycline inhibits the growth of glioma by inducing autophagy.(({{pubmed> | + | Minocycline inhibits the growth of glioma by inducing autophagy.(({{pmid> |
Minocycline effectively inhibited tumor growth and induced autophagy in the xenograft tumor model of C6 glioma cells. These results suggest that minocycline may kill glioma cells by inducing autophagic cell death. When autophagy was inhibited, minocycline still induced cell death through the activation of caspase-3. Thus, minocycline is a promising agent in the treatment of malignant gliomas. | Minocycline effectively inhibited tumor growth and induced autophagy in the xenograft tumor model of C6 glioma cells. These results suggest that minocycline may kill glioma cells by inducing autophagic cell death. When autophagy was inhibited, minocycline still induced cell death through the activation of caspase-3. Thus, minocycline is a promising agent in the treatment of malignant gliomas. | ||
Line 108: | Line 97: | ||
*Legacy content | *Legacy content | ||
- | * | + | |
+ | |||
+ | ===== References =====</ | ||
- | ===== References ===== |